NWBO also tends to wait so long that bad intervening events set back progress.
They waited so long to end the trial that COVID-19 hit.
Then they decided to delay so long that the FDA made the very controversial decision to approve Aduhelm approval and given that DCVAx-L is scarcely cheap, that does not bode well.
If NWBO has slam dunk data, that's one thing.
But if the data is muddy as you suggest, it might be that NWBO ends up getting a "No" or a "You need to do a new Phase 3 trial" not on the merits but because the FDA does not want to look bad again.
Hopefully the data is not muddy but does speak for itself.
If not, then we might have waited too long yet again.
Market Data 
Markets 
AI
